Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
| Autor: | Nigel Patton, Ian Prosser, Shir-Jing Ho, Tony Mills, John F. Seymour, Emma Link, Andrew Nicol, Diana Zannino, Mark Hertzberg, Melita Kenealy, Linda Cowan, Robin Filshie |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Adult Male Cancer Research medicine.medical_specialty Azacitidine Phases of clinical research Chronic myelomonocytic leukemia 03 medical and health sciences 0302 clinical medicine Bone Marrow hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Neoplasm Staging Quality of Health Care Aged 80 and over business.industry Myelodysplastic syndromes Myeloid leukemia Leukemia Myelomonocytic Chronic Hematology Middle Aged medicine.disease Survival Analysis Thalidomide Leukemia Leukemia Myeloid Acute 030104 developmental biology Treatment Outcome Hypomethylating agent 030220 oncology & carcinogenesis Immunology Female business medicine.drug |
| Zdroj: | Leukemialymphoma. 58(2) |
| ISSN: | 1029-2403 |
| Popis: | Single agent azacitidine or immunomodulatory drugs are effective in myelodysplastic syndrome (MDS), with differing target mechanisms and toxicities. Objectives of this ALLG MDS3 study in clinically advanced MDS, AMML and low blast AML were to establish safety, response and quality of life of azacitidine and thalidomide. Patients received azacitidine (75mg/m2/d sc 7days every 28 days), and oral thalidomide up to 100mg/d for maximum 12months. Eighty patients registered; median age 68 years (range 42-82), 49% IPSS int2-high. With 36.5 months follow up, patients received median 9 cycles azacitidine, 6.1mths thalidomide. Nonhematologic toxicity grade 3+ in 85%, commonly infections. Overall response rate was 63%; 26% CR were unaffected by IPSS. Median response duration 26.3months; overall survival was 28.1months. This combination azacitidine and thalidomide in clinically advanced MDS, CMML and low-blast AML was tolerable without unexpected toxicity and encouraging responses support further investigation of combination approaches with hypomethylating agent and immunomodulatory drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|